In addition to our assessments of the prognostic values of PRDX mRNA expressions in general GC patients, we further performed subtype analysis to assess the associations with different clinicopathological characteristics to identify more potential beneficiaries who may benefit from prognostic assessment using PRDX mRNA expressions, according to clinical stages, Lauren classifications, HER2 expression status, differentiation degree, and treatment strategies. This evidence concerns the gene ERBB2 and gastric cancer.